Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 50

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 50
---
ence

The Company derives over 85% of its sales and related
accounts receivable from one distribution partner, Symrise AG, a global supplier of fragrances, flavors, food nutrition, and cosmetic
ingredients, and the Company is continually seeking to expand its customer base. The Company’s future success in its base business
cosmeceuticals market is dependent upon the continued demand by this distributor and their underlying customers, and the expansion of
the Company’s customer base. Any decline in or loss of demand from this distributor or their underlying customers may have a negative
impact on the Company’s revenues and an adverse impact on its business, financial condition, and results of operations. On August
25, 2023, the Company announced the signing of an amendment to its exclusive long-term supply and distribution agreement with Symrise
AG. Pursuant to the amendment, the Company has extended the term of the agreement for two years to December 31, 2026.

The Company’s business growth depends on its
ability to access global markets through distribution partnerships. The Company’s marketing strategy emphasizes providing technical
support to its distributors and their customers to maximize the value of its technology and product utilization. The Company’s
vision and business strategy are supported by The Company’s commitment to the following core values:

  adding value to all aspects of the Company’s business;  

  enhancing the health of humans and animals;  

  discovering and commercializing new, therapeutic natural ingredients  

  producing the highest quality work possible in products, science and  

  developing personnel through guidance, opportunities and encouragement.  

To support these objectives, the Company relies on
strong intellectual and human capital resources and is developing a strong base of partnerships and strategic alliances to exploit the
Company’s technology. The current economic environment provides challenges in obtaining financial resources to fully exploit opportunities.
To fund its operations, the Company relies upon revenues primarily generated from the sale of active ingredients, the proceeds of public
and private offerings of equity securities and debentures, government grants and loans, and other investment offerings.

Regulation of Drug Development

Generally. Governmental authorities in the
U. S., Canada, Europe, and other countries extensively regulate the preclinical and clinical testing, manufacturing, labeling, storage,
record keeping, advertising, promotion, export, marketing, and distribution, among other things, of pharmaceuticals. Under the laws of
the U. S., the countries of the EU, and other countries, we are subject to obligations to ensure that our clinical trials are conducted